Yutaka Kawakami
Affiliations: | Keio University, Minato-ku, Tōkyō-to, Japan |
Google:
"Yutaka Kawakami"Mean distance: 16.96 (cluster 17)
Children
Sign in to add traineeYohei Ohashi | research assistant | 2000-2004 | Keio University |
Yukihiko Iizuka | grad student | 1999-2004 | Keio University |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Nakamura K, Yaguchi T, Murata M, et al. (2024) Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD-1 antibody for BRAF-mutated melanoma. Cancer Science |
Tamura R, Yamanobe Y, Fujioka M, et al. (2024) Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2302376 |
Ohta S, Misawa A, Kyi-Tha-Thu C, et al. (2023) Melanoma antigens recognized by T cells and their use for immunotherapy. Experimental Dermatology |
Morimoto Y, Tokumitsu A, Sone T, et al. (2022) TPT1 Supports Proliferation of Neural Stem/Progenitor Cells and Brain Tumor Initiating Cells Regulated by Macrophage Migration Inhibitory Factor (MIF). Neurochemical Research |
Wang B, Xu Z, Sunthamala N, et al. (2022) Combinatorial sympathetic and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockades inhibit the murine melanoma growth by targeting infiltrating T cells. Translational Cancer Research. 10: 899-913 |
Fukuda K, Okamura K, Riding RL, et al. (2021) AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma. The Journal of Experimental Medicine. 218 |
Hirai I, Funakoshi T, Kamijuku H, et al. (2021) Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors. Cancer Science |
Kinoshita T, Sayem MA, Yaguchi T, et al. (2021) Inhibition of vascular adhesion protein-1 enhances the anti-tumor effects of immune checkpoint inhibitors. Cancer Science |
Yamada K, Hazama S, Suzuki N, et al. (2021) Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer. Oncology Letters. 21: 10 |
Hayakawa T, Yaguchi T, Kawakami Y. (2020) Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3. Cancer Science |